Acción 3SBIO INC. (ADR)
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas 3SBio Inc. (ADR) Nasdaq

Acciones

US88575Y1055

Precio de cierre Nasdaq
Otros sitios de cotización
- USD - Gráfico intradía de 3SBio Inc. (ADR)
22/04 3Sbio Inc. anuncia cambios en la dirección CI
12/04 3SBio Inc. Aprueba la inyección de trombopoyetina humana recombinante (Tpiao) para la indicación de PTI pediátrica CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
3Sbio Inc. Announces Management Changes
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product
Mandi Foam of 3SBio Inc. Approves for Market Launch
Venus Medtech Names Former 3SBio Finance Chief as CFO
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
3SBio : 2023 Interim Results Presentation
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
3SBio Hires Former JPMorgan Exec as CFO
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer
3SBio Rolls Out Pruritus Medication in China
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 1530
  4. Acción
  5. Noticias 3SBio Inc. (ADR)
  6. Otros idiomas